Today, the CFO of Delcath Systems Inc (Other OTC: DCTH), Barbra Keck, bought shares of DCTH for $12.95K.
Following this transaction Barbra Keck’s holding in the company was increased by 7325.74% to a total of $4,463. In addition to Barbra Keck, 2 other DCTH executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Delcath Systems Inc’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $858K and GAAP net loss of $6.66 million. In comparison, last year the company earned revenue of $684K and had a GAAP net loss of $12.6 million. Currently, Delcath Systems Inc has an average volume of 339.5K.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes Melphalan Hydrochloride for Injection, which is a proprietary product for use with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.
